At the last check on Thursday, iBio Inc.’s (AMEX:IBIO) stock was down -$0.02, moving down -5.61 percent to $0.29. The average number of shares traded per day over the past five days has been 637,430 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0302 fall in that time frame. In the last twenty days, the average volume was 1,001,563, while in the previous 50 days, it was 604,535.
Since last month, IBIO stock retreated -41.65%. Shares of the company fell to $0.2851 on 08/31/23, the lowest level in the past month. A 52-week high of $16.51 was reached on 03/21/23 after having rallying from a 52-week low of $0.30. Since the beginning of this year, IBIO’s stock price has dropped by -34.18% or -$0.1534, and marked a new high 12 times. However, the stock has declined by -98.23% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
IBIO stock investors should be aware that iBio Inc. (IBIO) stock had its last reported insider trading activity 3 days ago on Aug 28. Brenner Martin disposed of 5,011 shares for $0.31 on Aug 28. It resulted in a $1,529 divestment by the insider. Brenner Martin sold 4,515 shares at an average price of $0.51 on Jul 27. The insider now owns 201,876 shares following the transaction. On Jul 12, Brenner Martin sold 47,020 shares at $0.59 apiece. The transaction was valued at $27,521.
Valuation Metrics
The stock’s beta is -3.17. Besides these, the trailing price-to-sales (P/S) ratio of 12.60, the price-to-book (PB) ratio of 0.22.
Financial Health
According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.04, and the total debt-to-equity ratio was 0.85. Based on annual data, IBIO earned $2.17 million in gross profit and brought in $2.38 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -57.30%. Return on equity (ROE) for the past 12 months was -205.40%.
While analysts expected iBio Inc. to report -$1.85 quarterly earnings, the actual figure was -$2.05 per share, beating the consensus estimate by -10.80%. During the quarter, the company generated -$5.84 million in EBITDA. The liabilities of iBio Inc. were 27.0 million at the end of its most recent quarter ended September 29, and its total debt was $18.43 million. The value of shareholders’ equity is $16.8 million.
Technical Picture
This quick technical analysis looks at iBio Inc.’s (IBIO) price momentum. With a historical volatility rate of 46.22%, the RSI 9-day stood at 22.01% on 30 August.
With respect to its five-day moving average, the current iBio Inc. price is down by -9.40% percent or -$0.0302. At present, IBIO shares trade -41.21% below its 20-day simple moving average and -74.70% percent below its 100-day simple moving average. However, the stock is currently trading approximately -56.70% below its SMA50 and -83.37% below its SMA200.
Stochastic coefficient K was 5.97% and Stochastic coefficient D was 8.10%, while ATR was 0.0430. Given the Stochastic reading of 3.11% for the 14-day period, the RSI (14) reading has been calculated as 26.32%. As of today, the MACD Oscillator reading stands at -0.0239, while the 14-day reading stands at -0.0565.
Analyst Ratings
JMP Securities launched its rating on iBio Inc. (AMEX: IBIO) to a Mkt outperform in a note to investors on November 29, 2021. iBio Inc. (IBIO) has been rated Hold by analysts. According to 0 brokerage firms, IBIO is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate iBio Inc. stock as buy, with 0 recommending it as overweight.
